HomeABUS • NASDAQ
add
Arbutus Biopharma Corp
Previous close
$4.41
Day range
$4.37 - $4.46
Year range
$2.71 - $5.10
Market cap
848.15M USD
Avg Volume
1.05M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 529.00K | -60.49% |
Operating expense | 3.04M | -32.91% |
Net income | -7.74M | 60.73% |
Net profit margin | -1.46K | 0.61% |
Earnings per share | -0.06 | 59.57% |
EBITDA | -8.28M | 51.67% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 93.70M | -26.68% |
Total assets | 97.71M | -30.43% |
Total liabilities | 20.31M | -39.46% |
Total equity | 77.40M | — |
Shares outstanding | 192.32M | — |
Price to book | 11.02 | — |
Return on assets | -20.63% | — |
Return on capital | -24.39% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -7.74M | 60.73% |
Cash from operations | -5.82M | 71.95% |
Cash from investing | -10.02M | 16.41% |
Cash from financing | 844.00K | -52.45% |
Net change in cash | -15.00M | 51.51% |
Free cash flow | -2.55M | 76.57% |
About
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Founded
2007
Headquarters
Website
Employees
44
